SlideShare a Scribd company logo

Biocon Investors Presentation July 2013

Biocon
Biocon
BioconBiocon

Biocon Investors Presentation July 2013

Biocon Investors Presentation July 2013

1 of 43
Download to read offline
Innovative Science
Affordable Medicine
www.biocon.com
Investor Presentation
July 2013
Certain statements in this release concerning our future growth prospects are forward-looking
statements, which are subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those contemplated in such forward-looking statements.
Important factors that could cause actual results to differ materially from our expectations include,
amongst others general economic and business conditions in India, our ability to successfully
implement our strategy, our research and development efforts, our growth and expansion plans and
technological changes, changes in the value of the Rupee and other currencies, changes in the Indian
and international interest rates, change in laws and regulations that apply to the Indian and global
biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the
Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and
changes in the foreign exchange control regulations in India. Neither the company, nor its directors and
any of the affiliates have any obligation to update or otherwise revise any statements reflecting
circumstances arising after this date or to reflect the occurrence of underlying events, even if the
underlying assumptions do not come to fruition.
Safe Harbor
2
Biocon: Who are we?
• Small Molecules
• Biosimilars
• Branded Formulations
• Research Services
• Novel Molecules
Growth Segments
Financials
Outlook
Agenda
3
Biocon: Who are We?
Biocon: Global Ambitions with Indian Roots
Mission: “To be an integrated biotechnology enterprise of global distinction”
Value Creation along 3 axes:
Leveraging the India advantage to deliver high value, licensable R&D assets
Strategic Research and marketing partnerships that provide global access
Reducing therapy costs of chronic diseases. (diabetes, cancer & auto-immune diseases)
5
Evolving with the Times
1978 -
1999
1999 -
2004
2004 -
2009
2009 –
2014
2014 &
Beyond
An Enzymes Company
Revenue: ` 32 Crores
Building the India Business
and expertise in biologics
Revenue: ` 1,194 Crores
People: 3,500+
Investment intensive phase with
focus on R&D, capacity &
partnership execution
Revenue (FY 13): ` 2,538 Crores
People: 6,700+
Transforming into a
Biopharma company
Revenues: ` 549 Crores
People: 700+
Unwavering focus through the years on Innovation & Difficult to make, niche
products to create tangible differentiators for sustainable growth
6
Poised for a global
platform with launch of
finished formulations &
biosimilars in regulated
markets
Ad

Recommended

Biocon FY2014 Results
Biocon FY2014 ResultsBiocon FY2014 Results
Biocon FY2014 ResultsBiocon
 
Biocon H1 FY13 Media Presentation
Biocon H1 FY13 Media PresentationBiocon H1 FY13 Media Presentation
Biocon H1 FY13 Media PresentationBiocon
 
Biocon Investor Presentation Jan 2013
Biocon Investor Presentation Jan 2013Biocon Investor Presentation Jan 2013
Biocon Investor Presentation Jan 2013Biocon
 
Biocon Investor Presentation_Sept_2011_Q1
Biocon Investor Presentation_Sept_2011_Q1Biocon Investor Presentation_Sept_2011_Q1
Biocon Investor Presentation_Sept_2011_Q1Biocon
 
Biocon an innovative and integrated bio-pharma company
Biocon   an innovative and integrated bio-pharma companyBiocon   an innovative and integrated bio-pharma company
Biocon an innovative and integrated bio-pharma companyHBJ Capital Services Pvt. Ltd
 
Biocon Investor's Presentation July 2014
Biocon Investor's Presentation July 2014Biocon Investor's Presentation July 2014
Biocon Investor's Presentation July 2014Biocon
 
Biocon’s nine months revenue continues to deliver steady growth in fy13
Biocon’s nine months revenue continues to deliver steady growth in fy13Biocon’s nine months revenue continues to deliver steady growth in fy13
Biocon’s nine months revenue continues to deliver steady growth in fy13Biocon
 
Biocon Press Conference FY13 Results - April 26, 2013
Biocon Press Conference FY13 Results - April 26, 2013 Biocon Press Conference FY13 Results - April 26, 2013
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
 

More Related Content

What's hot

Business Growth Strategy - Biocon
Business Growth Strategy -  BioconBusiness Growth Strategy -  Biocon
Business Growth Strategy - Bioconyuvrajgill
 
Biocon Q3 FY16 net profit up 13% at Rs.103 crore
Biocon Q3 FY16 net profit up 13% at Rs.103 croreBiocon Q3 FY16 net profit up 13% at Rs.103 crore
Biocon Q3 FY16 net profit up 13% at Rs.103 croreBiocon
 
Biocon India Case Study
Biocon India Case StudyBiocon India Case Study
Biocon India Case StudyANURAG GUPTA
 
Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon
 
151796866 bio con-case-study
151796866 bio con-case-study151796866 bio con-case-study
151796866 bio con-case-studyhomeworkping4
 
Ranbaxy laboratories project
Ranbaxy laboratories projectRanbaxy laboratories project
Ranbaxy laboratories projectNandita Sadani
 
Ranbaxy - Strategy management
Ranbaxy - Strategy managementRanbaxy - Strategy management
Ranbaxy - Strategy managementArchana Patel
 
Biocon case study group 1
Biocon case study group 1Biocon case study group 1
Biocon case study group 1ANURAG GUPTA
 
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Biocon
 
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
 
Sarita Sharma
Sarita SharmaSarita Sharma
Sarita Sharmariya50
 
Development of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaDevelopment of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaBhaswat Chakraborty
 
baxinco analysis Fsa repot full complited copy
baxinco analysis Fsa repot full complited copybaxinco analysis Fsa repot full complited copy
baxinco analysis Fsa repot full complited copySudipta Saha
 
Presentation at The 38th JP Morgan Healthcare Conference_English
Presentation at The 38th JP Morgan Healthcare Conference_EnglishPresentation at The 38th JP Morgan Healthcare Conference_English
Presentation at The 38th JP Morgan Healthcare Conference_EnglishNancy Ning Chen
 
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Tefen's Supply Chain Breakfast  Meeting - Sun PharmaTefen's Supply Chain Breakfast  Meeting - Sun Pharma
Tefen's Supply Chain Breakfast Meeting - Sun PharmaNir Gallner
 
Profitability analysis of beximco pharmaceutical s limited
Profitability analysis of beximco pharmaceutical s limitedProfitability analysis of beximco pharmaceutical s limited
Profitability analysis of beximco pharmaceutical s limitedRoni Bhowmik
 

What's hot (20)

Business Growth Strategy - Biocon
Business Growth Strategy -  BioconBusiness Growth Strategy -  Biocon
Business Growth Strategy - Biocon
 
Biocon Q3 FY16 net profit up 13% at Rs.103 crore
Biocon Q3 FY16 net profit up 13% at Rs.103 croreBiocon Q3 FY16 net profit up 13% at Rs.103 crore
Biocon Q3 FY16 net profit up 13% at Rs.103 crore
 
Biocon India Case Study
Biocon India Case StudyBiocon India Case Study
Biocon India Case Study
 
Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012
 
151796866 bio con-case-study
151796866 bio con-case-study151796866 bio con-case-study
151796866 bio con-case-study
 
Ranbaxy laboratories project
Ranbaxy laboratories projectRanbaxy laboratories project
Ranbaxy laboratories project
 
Ranbaxy - Strategy management
Ranbaxy - Strategy managementRanbaxy - Strategy management
Ranbaxy - Strategy management
 
Biocon case study group 1
Biocon case study group 1Biocon case study group 1
Biocon case study group 1
 
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...
 
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...
 
Sarita Sharma
Sarita SharmaSarita Sharma
Sarita Sharma
 
Development of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaDevelopment of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in India
 
baxinco analysis Fsa repot full complited copy
baxinco analysis Fsa repot full complited copybaxinco analysis Fsa repot full complited copy
baxinco analysis Fsa repot full complited copy
 
Presentation at The 38th JP Morgan Healthcare Conference_English
Presentation at The 38th JP Morgan Healthcare Conference_EnglishPresentation at The 38th JP Morgan Healthcare Conference_English
Presentation at The 38th JP Morgan Healthcare Conference_English
 
M&A in Pharma
M&A in PharmaM&A in Pharma
M&A in Pharma
 
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Tefen's Supply Chain Breakfast  Meeting - Sun PharmaTefen's Supply Chain Breakfast  Meeting - Sun Pharma
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
 
Biocon Company Profile
Biocon Company ProfileBiocon Company Profile
Biocon Company Profile
 
Profitability analysis of beximco pharmaceutical s limited
Profitability analysis of beximco pharmaceutical s limitedProfitability analysis of beximco pharmaceutical s limited
Profitability analysis of beximco pharmaceutical s limited
 
Sun pharma
Sun pharmaSun pharma
Sun pharma
 
Challenges in the changing pharmaceutical
Challenges in the changing pharmaceuticalChallenges in the changing pharmaceutical
Challenges in the changing pharmaceutical
 

Similar to Biocon Investors Presentation July 2013

Biocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014Fen Castro
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 Fen Castro
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014Virtue Insight
 
5th biosimilars congregation 2014
5th biosimilars congregation 20145th biosimilars congregation 2014
5th biosimilars congregation 2014Nisha Virtue
 
Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon
 
applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsRichard Littlewood
 
Biocon delivers healthy growth in H1FY13
Biocon delivers healthy growth in H1FY13 Biocon delivers healthy growth in H1FY13
Biocon delivers healthy growth in H1FY13 Biocon
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Debashish Kar
 
Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11rvdatar
 
Download Global biosimilars market regulations & pipeline insight
Download Global biosimilars market regulations & pipeline insightDownload Global biosimilars market regulations & pipeline insight
Download Global biosimilars market regulations & pipeline insightKuicK Research
 
Biocon Q4FY12_Investor Presentation_April_2012
Biocon Q4FY12_Investor Presentation_April_2012Biocon Q4FY12_Investor Presentation_April_2012
Biocon Q4FY12_Investor Presentation_April_2012Biocon
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars successRichard Littlewood
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars successRichard Littlewood
 
Syngene IPO feasibility analysis
Syngene IPO feasibility analysisSyngene IPO feasibility analysis
Syngene IPO feasibility analysisBurning Desires
 
Dyadic fact sheet august 2018
Dyadic fact sheet august 2018Dyadic fact sheet august 2018
Dyadic fact sheet august 2018Dyadic
 

Similar to Biocon Investors Presentation July 2013 (20)

Biocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact Sheet
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th biosimilars congregation 2014
5th biosimilars congregation 20145th biosimilars congregation 2014
5th biosimilars congregation 2014
 
Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon H1 q2fy10 11
Biocon H1 q2fy10 11
 
applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilars
 
Korea entry strategy (biocon)
Korea entry strategy (biocon)Korea entry strategy (biocon)
Korea entry strategy (biocon)
 
Korea entry strategy (biocon) Hypothetical
Korea entry strategy (biocon) HypotheticalKorea entry strategy (biocon) Hypothetical
Korea entry strategy (biocon) Hypothetical
 
Biocon delivers healthy growth in H1FY13
Biocon delivers healthy growth in H1FY13 Biocon delivers healthy growth in H1FY13
Biocon delivers healthy growth in H1FY13
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
 
Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11
 
Download Global biosimilars market regulations & pipeline insight
Download Global biosimilars market regulations & pipeline insightDownload Global biosimilars market regulations & pipeline insight
Download Global biosimilars market regulations & pipeline insight
 
Biocon Q4FY12_Investor Presentation_April_2012
Biocon Q4FY12_Investor Presentation_April_2012Biocon Q4FY12_Investor Presentation_April_2012
Biocon Q4FY12_Investor Presentation_April_2012
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars success
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars success
 
Industry analysis
Industry analysisIndustry analysis
Industry analysis
 
Syngene IPO feasibility analysis
Syngene IPO feasibility analysisSyngene IPO feasibility analysis
Syngene IPO feasibility analysis
 
Dyadic fact sheet august 2018
Dyadic fact sheet august 2018Dyadic fact sheet august 2018
Dyadic fact sheet august 2018
 

More from Biocon

Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
 
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
 
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 Biocon
 
Biocon Walk in Interviews at Hyderabad on May 22, 2016
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon Walk in Interviews at Hyderabad on May 22, 2016
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon
 
Biocon organizing walk-in interviews at Vishakhapatnam
Biocon organizing walk-in interviews at VishakhapatnamBiocon organizing walk-in interviews at Vishakhapatnam
Biocon organizing walk-in interviews at VishakhapatnamBiocon
 
Axis Capital Report recommends BUY Target Price 640
Axis Capital Report recommends BUY Target Price 640Axis Capital Report recommends BUY Target Price 640
Axis Capital Report recommends BUY Target Price 640Biocon
 
Biocon organizing walk-in interviews at Don Bosco College, Margao, Goa
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon organizing walk-in interviews at Don Bosco College, Margao, Goa
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon
 
Biocon Walkin Interviews Hyderabad 29th November 2015
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon Walkin Interviews Hyderabad 29th November 2015
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon
 
New Candidate Registration & Application Process: Navigation from Biocon.com
New Candidate Registration & Application Process: Navigation from Biocon.comNew Candidate Registration & Application Process: Navigation from Biocon.com
New Candidate Registration & Application Process: Navigation from Biocon.comBiocon
 
India's first Int'l Conference on Best Practices in Pharma Microbiology
India's first Int'l Conference on Best Practices in Pharma Microbiology India's first Int'l Conference on Best Practices in Pharma Microbiology
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
 
KSPCB'S Consent Letter to Biocon
KSPCB'S Consent Letter to BioconKSPCB'S Consent Letter to Biocon
KSPCB'S Consent Letter to BioconBiocon
 
Biocon Bio Waste Disposal Company Statement
Biocon Bio Waste Disposal Company Statement Biocon Bio Waste Disposal Company Statement
Biocon Bio Waste Disposal Company Statement Biocon
 
Biocon Walk-In Pondicherry 28th June 2015
Biocon Walk-In Pondicherry 28th June 2015Biocon Walk-In Pondicherry 28th June 2015
Biocon Walk-In Pondicherry 28th June 2015Biocon
 
Biocon Walk In Interview Available Positions 19th July 2014
Biocon Walk In Interview Available Positions 19th July 2014Biocon Walk In Interview Available Positions 19th July 2014
Biocon Walk In Interview Available Positions 19th July 2014Biocon
 
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
 
Biocon Walk-in Interview
Biocon Walk-in InterviewBiocon Walk-in Interview
Biocon Walk-in InterviewBiocon
 
Psoriasis FAQs
Psoriasis FAQsPsoriasis FAQs
Psoriasis FAQsBiocon
 
World Polio Day
World Polio DayWorld Polio Day
World Polio DayBiocon
 
Stop Using Tobacco
Stop Using TobaccoStop Using Tobacco
Stop Using TobaccoBiocon
 
Other heart diseases
Other heart diseasesOther heart diseases
Other heart diseasesBiocon
 

More from Biocon (20)

Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)
 
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016
 
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016
 
Biocon Walk in Interviews at Hyderabad on May 22, 2016
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon Walk in Interviews at Hyderabad on May 22, 2016
Biocon Walk in Interviews at Hyderabad on May 22, 2016
 
Biocon organizing walk-in interviews at Vishakhapatnam
Biocon organizing walk-in interviews at VishakhapatnamBiocon organizing walk-in interviews at Vishakhapatnam
Biocon organizing walk-in interviews at Vishakhapatnam
 
Axis Capital Report recommends BUY Target Price 640
Axis Capital Report recommends BUY Target Price 640Axis Capital Report recommends BUY Target Price 640
Axis Capital Report recommends BUY Target Price 640
 
Biocon organizing walk-in interviews at Don Bosco College, Margao, Goa
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon organizing walk-in interviews at Don Bosco College, Margao, Goa
Biocon organizing walk-in interviews at Don Bosco College, Margao, Goa
 
Biocon Walkin Interviews Hyderabad 29th November 2015
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon Walkin Interviews Hyderabad 29th November 2015
Biocon Walkin Interviews Hyderabad 29th November 2015
 
New Candidate Registration & Application Process: Navigation from Biocon.com
New Candidate Registration & Application Process: Navigation from Biocon.comNew Candidate Registration & Application Process: Navigation from Biocon.com
New Candidate Registration & Application Process: Navigation from Biocon.com
 
India's first Int'l Conference on Best Practices in Pharma Microbiology
India's first Int'l Conference on Best Practices in Pharma Microbiology India's first Int'l Conference on Best Practices in Pharma Microbiology
India's first Int'l Conference on Best Practices in Pharma Microbiology
 
KSPCB'S Consent Letter to Biocon
KSPCB'S Consent Letter to BioconKSPCB'S Consent Letter to Biocon
KSPCB'S Consent Letter to Biocon
 
Biocon Bio Waste Disposal Company Statement
Biocon Bio Waste Disposal Company Statement Biocon Bio Waste Disposal Company Statement
Biocon Bio Waste Disposal Company Statement
 
Biocon Walk-In Pondicherry 28th June 2015
Biocon Walk-In Pondicherry 28th June 2015Biocon Walk-In Pondicherry 28th June 2015
Biocon Walk-In Pondicherry 28th June 2015
 
Biocon Walk In Interview Available Positions 19th July 2014
Biocon Walk In Interview Available Positions 19th July 2014Biocon Walk In Interview Available Positions 19th July 2014
Biocon Walk In Interview Available Positions 19th July 2014
 
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...
 
Biocon Walk-in Interview
Biocon Walk-in InterviewBiocon Walk-in Interview
Biocon Walk-in Interview
 
Psoriasis FAQs
Psoriasis FAQsPsoriasis FAQs
Psoriasis FAQs
 
World Polio Day
World Polio DayWorld Polio Day
World Polio Day
 
Stop Using Tobacco
Stop Using TobaccoStop Using Tobacco
Stop Using Tobacco
 
Other heart diseases
Other heart diseasesOther heart diseases
Other heart diseases
 

Recently uploaded

The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar Levels
The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar LevelsThe Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar Levels
The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar LevelsAman Ullah
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchDr KHALID B.M
 
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxTRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxPoojaDahale3
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfKoppala RVS Chaitanya
 
how to look more attractive? | Boys Edition
how to look more attractive? | Boys Editionhow to look more attractive? | Boys Edition
how to look more attractive? | Boys Editionalibieb33d
 
Dental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classDental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classHVCClibrary
 
Seminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfSeminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfsusiedapp
 
Seminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosSeminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosAuraCristinaPeaSanto
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementeshasmalik27
 
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxBiochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxRajendra Dev Bhatt
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkClinicians
 
Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfMedicoseAcademics
 
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Abhinav S
 
Emergency-First-Aid-Made-Easy-Training-Presentation.pptx
Emergency-First-Aid-Made-Easy-Training-Presentation.pptxEmergency-First-Aid-Made-Easy-Training-Presentation.pptx
Emergency-First-Aid-Made-Easy-Training-Presentation.pptxDrSathishMS1
 
Introducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessIntroducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessFredrick Amos
 
pediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptpediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptArun170190
 

Recently uploaded (20)

The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar Levels
The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar LevelsThe Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar Levels
The Natural Method That Supports Healthy Weight Loss & Steady Blood Sugar Levels
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical Research
 
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxTRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
 
Expectorants and Antitussives.pdf
Expectorants and Antitussives.pdfExpectorants and Antitussives.pdf
Expectorants and Antitussives.pdf
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdf
 
how to look more attractive? | Boys Edition
how to look more attractive? | Boys Editionhow to look more attractive? | Boys Edition
how to look more attractive? | Boys Edition
 
Dental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classDental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd class
 
Digestants and Carminatives.pdf
Digestants and Carminatives.pdfDigestants and Carminatives.pdf
Digestants and Carminatives.pdf
 
Seminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfSeminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdf
 
Seminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosSeminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña Santos
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic management
 
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxBiochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blink
 
Introduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptxIntroduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptx
 
Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdf
 
Respirtory stimulants.pdf
Respirtory stimulants.pdfRespirtory stimulants.pdf
Respirtory stimulants.pdf
 
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
Circulatory shock Cardiogenic Shock Hypovolemic Shock Sepsis, Septic Shock an...
 
Emergency-First-Aid-Made-Easy-Training-Presentation.pptx
Emergency-First-Aid-Made-Easy-Training-Presentation.pptxEmergency-First-Aid-Made-Easy-Training-Presentation.pptx
Emergency-First-Aid-Made-Easy-Training-Presentation.pptx
 
Introducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessIntroducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitness
 
pediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptpediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.ppt
 

Biocon Investors Presentation July 2013

  • 2. Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Safe Harbor 2
  • 3. Biocon: Who are we? • Small Molecules • Biosimilars • Branded Formulations • Research Services • Novel Molecules Growth Segments Financials Outlook Agenda 3
  • 5. Biocon: Global Ambitions with Indian Roots Mission: “To be an integrated biotechnology enterprise of global distinction” Value Creation along 3 axes: Leveraging the India advantage to deliver high value, licensable R&D assets Strategic Research and marketing partnerships that provide global access Reducing therapy costs of chronic diseases. (diabetes, cancer & auto-immune diseases) 5
  • 6. Evolving with the Times 1978 - 1999 1999 - 2004 2004 - 2009 2009 – 2014 2014 & Beyond An Enzymes Company Revenue: ` 32 Crores Building the India Business and expertise in biologics Revenue: ` 1,194 Crores People: 3,500+ Investment intensive phase with focus on R&D, capacity & partnership execution Revenue (FY 13): ` 2,538 Crores People: 6,700+ Transforming into a Biopharma company Revenues: ` 549 Crores People: 700+ Unwavering focus through the years on Innovation & Difficult to make, niche products to create tangible differentiators for sustainable growth 6 Poised for a global platform with launch of finished formulations & biosimilars in regulated markets
  • 7. Group Revenue at ` 723 Crores (22% YoY growth) YoY Growth* across verticals: EBITDA at ` 175 Crores (EBITDA Margin: 24% ) R&D Expense: ` 43 Crores (10 % of Biopharma Revenue) PAT at ` 94 Crores (PAT Margin: 13% ) Financial Performance Q1 FY14 Highlights 8*YoY comparison of Q1 FY14 Sales vs. Q1 FY13 Sales; #CER: Constant Exchange Rates Business Vertical Absolute Growth Growth at CER# Biopharma 21% 19% Branded Formulations 17% N.A. Total Biopharma 20% 19% Research Services 26% 22% Total Sales 22% 20%
  • 8. Novel Molecules Unlock Value through Licensing Growth Verticals ANDAs & 505(b)(2) filings Small Molecules Research Services Integrated offerings Insulins, MAbs & Other Biologics Biosimilars (Biologics & Insulins) Rapidly growing- India-centric business Branded Formulations EMERGING MARKETS FOCUSEMERGING MARKETS FOCUS Growth Verticals: Aligned with Shifting Paradigms 9
  • 9. Aligning For Growth: Reorganizing for greater synergy Function Based Organization -----> Business Units Sustaining the Entrepreneurial Spirit: Agility in decision making Responsibility with Accountability Greater Synergy amongst functions: Aligning people to the greater goal Marketing Finance Manufacturing Small Molecules Generic Insulins Biosimilar MAbs … … Earlier Organization Structure New Organization Structure 10 R&D Branded Formulations
  • 11. Small Molecules APIs (Generic & Novel) Formulations 505(b)(2) & ANDAs Current Portfolio Constituents Statins Simvastatin, Atorvastatin, Lovastatin, Rosuvastatin, Fluvastatin & Pravastatin Immuno suppressants Tacrolimus, MMF & MPA Other Biopharma Orlistat, Fidaxomicin, 50+ other molecules Product Portfolio which leverage our core fermentation capabilities and have a high degree of complexity Early mover in niche products coupled with economies of scale. Portfolio based Approach 12
  • 12. Biosimilars: Demystifying “a biological product that is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and.. no clinically meaningful differences against the reference product in terms of the safety, purity and potency.” Large Molecules (proteins): greater complexity Very difficult to make and demonstrate bio-similarity; Extensive development process Process development and Capacity constraints Insulin & Insulin Analogs (4) Monoclonal Antibodies (3) Other Biologics (2) A biosimilar is… Unlike a small molecule… Current Portfolio Biosimilar Definition: Biologics Price Competition and Innovation Act of 2009 13
  • 13. Herceptin ~6 Bn, 18% Avastin ~6 Bn, 18% Enbrel ~8 Bn, 24% Humira ~10 Bn,28% Neulasta ~4 Bn, 12% rh-Insulin ~ 3 Bn, 18% Glargine ~7 Bn, 35% Lispro ~2 Bn, 13% Aspart ~4 Bn, 23% Detemir ~2 Bn, 9% Glulisine ~0.3 Bn, 2% Biosimilars: Opportunity Total Insulins Market: ~ USD 19 Bn* The Insulin Pie Biosimilar MAbs & Other Biologic Opportunity : ~ USD 34 Bn* *Market Size of innovator products MAT March 2013, All figures rounded off to nearest USD Billion, %ages on absolute numbers 14
  • 14. Combines Biocon's R&D and manufacturing prowess of biologics with Mylan’s regulatory & commercialization capabilities in the US and Europe *Market Size of innovator products in the current portfolio: MAT March 2013 Generic Insulin Analogs Biosimilar MAbs & other Biologics Global Market Size * ~ USD 14 Bn ~ USD 34 Bn Portfolio Constituents Glargine, Lispro & Aspart Trastuzumab, Bevacizumab, Adalimumab, Eternacept, Peg-filgrastim Mylan’s Exclusive Commercialization Regions US, Canada, Europe, Australia & New Zealand All regulated markets Upfront Received $ 20 Mn $ 18 Mn Structure: Upfront Payment + Cost Sharing + Supplies + Profit Sharing# Mylan and Biocon to share development and capital costs #Profit Sharing Arrangement in regions where Mylan has exclusive commercialization rights Biocon and Mylan have co-exclusive commercialization rights in other markets. Co-Development & Commercialization Partnership 15 Biosimilars: Collaboration
  • 15. Portfolio Biosimilar Molecule Global Trials Generic Insulins rh- Insulin Glargine Lispro & Aspart Biosimilar MAbs and other biologics Trastuzumab Bevacizumab, Adalimumab Etanercept, Peg-filgrastim Process Development / Scale-up / Preclinical Phase 1/II b Market Phase III Emerging Markets First strategy coupled with a regional partnership commercialization approach Biosimilar Trastuzumab: patient recruitment completed for India Phase III trial. Generic rh Insulin registered in 45+ countries; generic insulin glargine registered in 10+ nations 16 Biosimilars: Pipeline
  • 16. 16 Biocon’s First Manufacturing expansion overseas : Iskandar, Johor Asia’s largest integrated Insulins manufacturing facility Investment to the tune of ~$ 160 Mn in the first phase Development on-going at full steam 1st Phase expected to be completed by 2014 Key Highlights Biosimilars: Malaysia Insulin Facility
  • 17. 17 Branded Formulations: Snapshot • An India Centric Business with Global Ambitions • Front Ending of our vertically integrated API & Biologics pipeline • Portfolio highlights: • Insugen & Basalog: India’s largest selling generic insulin & analog • BioMAb EGFR: India’s 1st indigenous novel MAb for head & neck cancer
  • 18. INDIA PRODUCT RANKINGS# Cardiology Clotide 1 Myokinase 2 Oncotherapeutics Evertor 1 BioMAb EGFR 2 Abraxane 3 Immunotherapy Calpsor C, Picon, Tbis 2 Nephrology Tacrograf 3 Bio-products Ivnex 2 Comprehensive Care Genpirome & Cegava TZ 2 #: ORG IMS Latest MAT 2013, IPSOS Branded Formulations: Sustained Growth 18 65 86 259 347 101 FY 12 FY13 FY14 Revenues in ` crore Q1
  • 19. * Includes biosimilars # Market Share as per latest MAT reports, IPSOS, LASSCHN Branded Formulations 19 Biologics* Remaining Portfolio India’s Fastest growing Insulin company Biocon: 34% | Sanofi: 15% | Novo: 5% #4 in overall insulin market #3 in the 40 IU Insulin market #1 in the Glargine vial market Biocon’s Volume Market share# 100 IU Insulin: 21% Glargine vials: 84% 79 130 179 107 130 169 186 259 347 FY11 FY12 FY13 Revenues in ` crore Market Share # of other flagship brands: BioMAb EGFR: 50% Evertor: 46% Picon: 33% Calpsor C: 34%
  • 20. Novel Molecules: Pipeline Therapeutic Area Molecule Oncology Nimotuzumab Autoimmune Itolizumab Diabetes IN-105 Oncology Anti CD – 20 Oncology Fusion Proteins Pre- Clinical Phase II Phase 1 Market Phase III Discovery # India Trials Itolizumab: India Commercial Launch in Q2 FY14 Anti CD 20 (BVx 20) has entered the clinic in India Multiple Global Trials planned for Oral Insulin in collaboration with BMS 20 Currently on hold
  • 21. Biocon will continue global development of the molecule through Phase II via redesigned trials. Partnership encompasses Financial, Strategic and Clinical Support throughout the development phase BMS will have an exclusive option post phase II to further develop & commercialise the asset worldwide (excl. India) Biocon will receive licensing fee in addition to potential regulatory & commercialization milestones, when BMS exercises its option Combines Biocon's novel asset and development experience with BMS’ novel drug development, regulatory & commercialization capabilities. Novel Molecules: Collaboration IN-105 Option Agreement: BMS (First-in-Class Oral Prandial Insulin) 21
  • 22. Novel Molecules: Itolizumab Profile First-in-Class Therapy :Novel MOA with an excellent safety profile Very low Infection rates vis-à-vis other approved therapies Modulates TH17 Pathway: Frontrunner in the hot bed of research in auto immune space Marketing Approval received in India post a successful Phase III trial in Psoriasis (200+ patients); Commercial launch in Q2 FY14 Excellent clinical remission & safety data in phase III for Psoriasis Promising preclinical and clinical efficacy data in other auto immune diseases (Rheumatoid Arthritis, Psoriatic Arthritis etc) Key Differentiators 28 Weeks12 WeeksBaseline 22
  • 23. Research Services: Snapshot 2000 Today India’s largest CRO with 1,500 + scientists, working with 16 of the Top 20 pharma companies in the world. Capital Investment of ~$120 Mn An investment of ~$20 Mn supported by 100+ scientists focused on building a world class CRO 23
  • 24. Customized models Evolving Services Niche Offerings Integrated Platforms o Bioanalytical testing of small and large molecules o Antibody Drug Conjugate (ADC) development o Unique In-Vivo Models- Human tumour tissue Xenograft o Early and rapid toxicology evaluation (Cardiomyocytes ) o Commercial scale production of NCEs o High potency (cytotoxic) API manufacturing o Formulation development o Dedicated/customized infrastructure o End-to-end services o Risk sharing: Milestone based o Incubation: IP sharing o Integrated Drug Discovery and Development o Biologics Discovery and Development o Syngene- Clinigene axis Research Services: Capabilities & Collaboration Models 24
  • 25. Research Services: Key Customers o Dedicated Infrastructure: Abbott Nutrition and R&D Centre o India focused product development addressing local needs with customized offerings tailored to local taste & texture preferences o Long term contract for 50+ FTEs focused on: • Maternal & Child Nutrition • Diabetes Care o Dedicated Infrastructure: BMS Biocon Research Centre o BMS’ largest research facility outside the US o 7 years contract, currently in its 4th year of operations o 450+ FTEs committed to integrated (end-to-end) research in a variety of therapeutic areas 25
  • 26. 72 88 124 155 318 410 557 FY 11 FY 12 FY 13 FY 14 Research Services: Performance o PE Investment of ` 125 Crores for a 7.69% stake, assigning Syngene a post money valuation of `1,625 Crores o Investment earmarked for enhancing Syngene’s service offerings, capacities & fund future growth o GE brings in corporate best practices along with avenues for capability enhancement and new offerings 26 Revenues in ` crore Q1
  • 28. Revenue 1,194 260 1,493 318 1,858 407 2,148 445 2,538 467 R&D Spend 60 13 79 17 118 26 137 28 164 137 EBITDA 372 81 455 97 573 125 579 120 596 110 Net profit 238 52 273 58 340 74 338 70 509 94 EPS (FV: ` 5) 11.9 13.6 17.0 16.9 25.4 FY09 FY10 FY11 FY12 FY08-12: Avg.exch.rate in that fiscal : 1Q FY13: USD 1 = ` 55.86; 1Q FY14: USD 1= ` 54.64 # Biopharma Sales excluding branded Formulations Financial Performance Q1 FY14 Q1 FY13 Revenue 723 | 129 593 | 108 R&D Spends 43 | 8 36 | 6 % of Biopharma Sales # 10% 10% EBITDA 175| 31 139 | 25 EBITDA Margin 24% 23% Net Profit 94| 17 79 | 14 PAT Margin 13% 13% EPS 4.7 3.9 All Figures in ` Crore /USD Mn except EPS FY13 28
  • 29. 349 432 86 101 122 155593 723 Q1 FY13 Q1 FY14 Regulated Markets* 56%India 28% RoW 16% Revenue: Detailed 29 All Figures in ` crore unless otherwise specified Core Biopharma Licensing Branded Formulations Research Services Other Income Geography Wise Sales Breakup: ` 723 *: Including Deemed Exports
  • 30. Core Business Margins: Detailed FY 09 FY 10 FY 11 FY 12 FY 13 Q1 FY14 Revenue 1,194 1,493 1,858 2,148 2,538 723 Less: Other Income 54 32 52 99 110 28 Less: Licensing Income 12 51 153 127 25 8 Core Revenues 1,127 1,410 1,654 1,922 2,403 687 EBITDA 372 455 573 579 596 175 Add: R&D Expense 60 79 118 137 164 43 Less: Other Income 54 32 52 99 110 28 Less: Licensing Income 12 51 153 127 25 8 Net EBITDA 365 450 487 490 625 182 EBITDA Margin 32% 32% 29% 25% 26% 26%
  • 32. 49% 5% 20% 10% 10% 40% 10% 25% 20% 5% 30% 20% 25% 20% 5% FY 12 A 2015 E 2018 E Small Molecules Biosimilars (Insulins + MAbs) Research Services Branded Formulation Licensing & Other Income ~ $450 Mn $1 Billion + ~ $700 Mn 31 Targeting $1 Bn Revenues in 5 Years Exchange Rate: 1 USD =` 50
  • 33. • Commercialization of generic rh-Insulin in regulated markets • Launch of generic insulin glargine in large semi-regulated markets • Commercialization of biosimilar trastuzumab in India & other emerging markets • Clinical development of generic rh-Insulin for US Biosimilars: Global Development & Commercialization • Generic insulin plant in Malaysia comes on stream: augmenting capacity and cost advantage • Research Services add further facilities & capabilities to catalyze the next growth wave Capacity Enhancement • Development/Commercialization partnership in developed markets: generic rh-insulin, Itolizumab • Emerging Market partnerships for small molecules & biosimilars Partnerships Key Milestones: 2015 E 32
  • 34. o Small Molecules - Improved product Mix o Research Services - Sustained Growth Momentum o Branded Formulations - Differentiated Value offerings o Biosimilars - Geographical Expansion in regulated markets o Novel Molecules - Out-licensing and Global Development Growth drivers supplemented by addition of new offerings (products, services & partnerships) Reaching $1 Bn by 2018 33 Looking Ahead 30% 20% 25% 20% 5% Exchange Rate: 1 USD =` 50
  • 35. • Continuous evolution of the biosimilar & therapeutic regulatory landscape in major regulated markets • Regulatory approvals, Patient enrollment, R&D development, process refinement etc. determine the pace and quantum of the R&D activities Biosimilars & Novel Molecules: Regulatory Clarity • Relationship management: New Contracts, Contract Renewal & Scope Expansion R&D Outsourcing: Research Services Partnership Management 34 Risks…
  • 36. www.biocon.com Innovative Science Affordable Medicine Investor Contact: Saurabh Paliwal Sweta Pachlangiya saurabh.paliwal@biocon.com sweta.pachlangiya@biocon.com
  • 38. ~955 ~70 ~180 ~1,205 2011 A Developed Markets Emerging Markets 2016 E USD Bn ~ 5% CAGR Global Pharma Market Source: IMS Institute of Healthcare informatics,The Global Use of Medicines: Outlook Through 2016 Emerging Markets to contribute ~ 75% of the Total Pharma Growth by 2016 Global Pharma Spending expected to cross $1.2 Trillion by 2016 Emerging Markets projected growth CAGR: ~10% Developed Markets expected growth CAGR: ~2% Emerging Markets growth driven by: Increased Government Healthcare Spending Growing Affluence Global Pharma Growth Catalyst: Emerging Markets 37
  • 39. *includes: OTC, diagnostics and non-therapeutics sales worth $118 Bn in 2011 and $145 Bn in 2016 E Global Pharma Growth Catalyst: Generics & Biosimilars Source: IMS Institute for Healthcare Informatics, IMS Market Prognosis, May 2012 Small Molecules, ~ 425 Biosimilars ~5 Small Molecules, ~ 241 Biosimilars ~ 1 Generic Spending to Increase by ~75% in the next 5 years vs. Branded drugs’ growth of 9% Biosimilars will grow 5 fold to $5 Bn 956 ~1,205 USD Bn Branded* 714 Branded* 745 Generic 242 Generic 430 2011 2016 E Back 38
  • 40. Small Molecules & Biosimilars: Comparison (1) Small Molecules Molecular Weight: Less than 700 Daltons Synthetic, Organic compounds [Chemistry based products] Well defined structure & relatively stable Monoclonal Antibody Molecular Weight: ~150,000 Daltons (~250x in size) Biologics- prepared in living organisms [Proteins] Complex physiochemical characteristics & heat sensitive 39
  • 41. Small Molecules & Biosimilars: Comparison (2) Regulatory Requirements PK/PD (establishing BA/BE) CMC Studies Clinical Trial PK/PD studies Preclinical studies Biological Characterization Physio-chemical Characterization Generics: Small Molecules Biosimilars 40
  • 43. ~61% | Promoters ~ 8 % | Employees & ESOP trust ~31 % | Public Biocon Business Structure & Holdings Syngene International, India | ~88% Custom research, drug discovery Clinigene International, India | 100% Clinical development Biocon Research , India | 100% R&D- Novel Molecules Biocon Biopharmaceuticals | 100% MAbs and Biosimilars Biocon Sdn. Bhd, Malaysia | 100% Overseas subsidiary Biocon SA, Switzerland | 100% Overseas subsidiary NeoBiocon, UAE | 50% Overseas subsidiary BIOPHARMA SUBSIDIARIES RESEARCH SERVICES Spanning the entire Value Chain with capabilities ranging from discovery to manufacturing 42